Invention Grant
- Patent Title: Fusion proteins that facilitate cancer cell destruction
-
Application No.: US15830923Application Date: 2017-12-04
-
Publication No.: US11332539B2Publication Date: 2022-05-17
- Inventor: Mark L. Tykocinski
- Applicant: THOMAS JEFFERSON UNIVERSITY
- Applicant Address: US PA Philadelphia
- Assignee: THOMAS JEFFERSON UNIVERSITY
- Current Assignee: THOMAS JEFFERSON UNIVERSITY
- Current Assignee Address: US PA Philadelphia
- Agency: Saul Ewing Arnstein & Lehr LLP
- Agent Kathryn Doyle
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K14/525 ; C07K14/705 ; C07K14/78 ; C07K14/47 ; A61K38/00
Abstract:
Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment.
Public/Granted literature
- US20180148512A1 FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTION Public/Granted day:2018-05-31
Information query
